Floatz logo

Valganciclovir

Accelerated Phase Chronic Myelogenous Leukemia

City of Hope Medical CenterSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Accelerated Phase Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
University of Illinois at Chicago
Phase 2BBB
Cyclophosphamide
University of Illinois at Chicago
Phase 2BBB
CYCLOSPORIN A
University of Michigan Rogel Cancer Center
Phase 2BBB
METHOTREXATE
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB

View all 46 →

Same molecule, other indications

Valganciclovir is also rated in:

cytomegalovirus infectionDormant
BB
Indicative ·
68 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
61 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →